Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Price Target Raised to $60.00

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) had its price target raised by Citigroup from $50.00 to $60.00 in a report published on Wednesday,Benzinga reports. Citigroup currently has a buy rating on the stock.

A number of other equities analysts have also weighed in on KNSA. Weiss Ratings reiterated a “hold (c)” rating on shares of Kiniksa Pharmaceuticals International in a report on Tuesday, April 21st. Jefferies Financial Group lifted their price target on shares of Kiniksa Pharmaceuticals International from $58.00 to $71.00 and gave the company a “buy” rating in a report on Tuesday. Zacks Research lowered shares of Kiniksa Pharmaceuticals International from a “hold” rating to a “strong sell” rating in a report on Friday, April 17th. Wedbush lifted their price target on shares of Kiniksa Pharmaceuticals International from $58.00 to $59.00 and gave the company an “outperform” rating in a report on Wednesday. Finally, Canaccord Genuity Group initiated coverage on shares of Kiniksa Pharmaceuticals International in a report on Thursday, February 19th. They set a “buy” rating and a $62.00 target price on the stock. Seven analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $60.86.

Kiniksa Pharmaceuticals International Trading Up 2.8%

Shares of KNSA traded up $1.49 during mid-day trading on Wednesday, reaching $55.27. The company had a trading volume of 1,021,780 shares, compared to its average volume of 855,419. The stock has a market cap of $4.23 billion, a price-to-earnings ratio of 61.41 and a beta of 0.17. The firm has a fifty day simple moving average of $46.40 and a 200-day simple moving average of $43.12. Kiniksa Pharmaceuticals International has a fifty-two week low of $24.85 and a fifty-two week high of $55.28.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last announced its quarterly earnings results on Tuesday, April 28th. The company reported $0.27 earnings per share for the quarter, beating analysts’ consensus estimates of $0.18 by $0.09. The company had revenue of $214.27 million for the quarter, compared to analyst estimates of $206.11 million. Kiniksa Pharmaceuticals International had a net margin of 9.69% and a return on equity of 13.26%. Kiniksa Pharmaceuticals International’s revenue for the quarter was up 55.5% on a year-over-year basis. During the same quarter last year, the business earned $0.11 EPS. As a group, equities analysts predict that Kiniksa Pharmaceuticals International will post 1.22 EPS for the current fiscal year.

Insider Buying and Selling at Kiniksa Pharmaceuticals International

In related news, CAO Michael R. Megna sold 6,625 shares of Kiniksa Pharmaceuticals International stock in a transaction on Thursday, April 9th. The shares were sold at an average price of $46.69, for a total transaction of $309,321.25. Following the transaction, the chief accounting officer owned 27,418 shares in the company, valued at approximately $1,280,146.42. The trade was a 19.46% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Mark Ragosa sold 17,845 shares of Kiniksa Pharmaceuticals International stock in a transaction on Monday, February 9th. The shares were sold at an average price of $43.28, for a total transaction of $772,331.60. Following the transaction, the chief financial officer owned 12,086 shares in the company, valued at $523,082.08. The trade was a 59.62% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 631,482 shares of company stock worth $32,528,087. Insiders own 53.48% of the company’s stock.

Hedge Funds Weigh In On Kiniksa Pharmaceuticals International

Hedge funds and other institutional investors have recently made changes to their positions in the business. Qube Research & Technologies Ltd increased its stake in Kiniksa Pharmaceuticals International by 277.8% during the 2nd quarter. Qube Research & Technologies Ltd now owns 888,364 shares of the company’s stock worth $24,581,000 after buying an additional 653,236 shares during the period. Rubric Capital Management LP increased its stake in Kiniksa Pharmaceuticals International by 15.6% during the 2nd quarter. Rubric Capital Management LP now owns 3,909,806 shares of the company’s stock worth $108,184,000 after buying an additional 526,567 shares during the period. Cubist Systematic Strategies LLC increased its stake in Kiniksa Pharmaceuticals International by 213.2% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 657,475 shares of the company’s stock worth $18,192,000 after buying an additional 447,536 shares during the period. Spruce Street Capital LP purchased a new stake in Kiniksa Pharmaceuticals International during the 4th quarter worth $17,943,000. Finally, SG Americas Securities LLC increased its stake in Kiniksa Pharmaceuticals International by 288.6% during the 4th quarter. SG Americas Securities LLC now owns 541,396 shares of the company’s stock worth $22,333,000 after buying an additional 402,078 shares during the period. Institutional investors and hedge funds own 53.95% of the company’s stock.

Key Kiniksa Pharmaceuticals International News

Here are the key news stories impacting Kiniksa Pharmaceuticals International this week:

• Positive Sentiment: Q1 beat and upgraded guidance — Kiniksa reported $0.27 EPS vs. $0.18 consensus and revenue of $214.3M (≈+55% YoY); management raised FY‑2026 revenue guidance, improving near‑term revenue visibility. Q1 Results & Guidance
• Positive Sentiment: Analyst upgrades/target raises — multiple brokers lifted targets (examples: Jefferies to $71, Canaccord to $64, Citi to $60, Wedbush to $59), which supports buying interest and helped push the stock higher. Analyst Target Raises
• Positive Sentiment: Product and pipeline momentum — ARCALYST reported strong Q1 net product revenue and management raised expectations; KPL‑387 Phase‑2 readout (recurrent pericarditis) is expected 2H‑2026 with a planned Phase‑3 start by year‑end, offering future catalysts. Product & Pipeline
• Neutral Sentiment: Earnings materials available — Q1 slide deck and call transcript posted for investors who want to verify channel dynamics, margin assumptions and guidance drivers. Earnings Presentation
• Negative Sentiment: Large insider selling — CEO Sanj K. Patel executed significant sales (including 483,654 shares on Apr. 28 and additional tranches Apr. 29–30) under a pre‑arranged 10b5‑1 plan; director Barry Quart also sold ~13k shares. Heavy insider selling can create short‑term negative sentiment despite being pre‑planned. CEO SEC Filing
• Negative Sentiment: Director sale detail — Director Barry D. Quart sold 13,099 shares (~$50.10 avg) under a 10b5‑1 plan, reducing his stake materially; additional SEC filing here. Director SEC Filing

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.